文献速递神经肿瘤

颅内脑膜瘤患者来源类器官模型新建成功

Newly established patient-derived organoid model of intracranial meningioma.
PubMed 文献 · Neuro Oncol · 2021-01-01

研究利用脑膜瘤细胞和组织建立类器官培养,并通过组织学和分子分析比较类器官与亲本肿瘤的一致性。共建立18个类器官模型,发现FOXM1上调与肿瘤增殖相关,FOXM1抑制剂thiostrepton联合放疗可显著抑制恶性脑膜瘤类器官增殖。

要点

  • 成功建立18个脑膜瘤类器官模型,保留亲本肿瘤组织学和分子特征
  • FOXM1上调与脑膜瘤增殖增加相关,过表达促进良性类器官增殖
  • thiostrepton联合放疗显著抑制恶性脑膜瘤类器官增殖

核心结论

  • 脑膜瘤类器官模型可再现亲本肿瘤组织学与分子特征,并用于发现FOXM1等治疗靶点。
  • thiostrepton联合放疗显著抑制恶性脑膜瘤类器官模型的增殖。

研究设计与样本

  • 利用脑膜瘤细胞和脑膜瘤肿瘤组织进行类器官培养。
  • 采用免疫组化和全外显子测序、RNA-seq、DNA甲基化分析比较类器官与亲本肿瘤。

主要发现

  • 共建立18个类器官模型,包括2株恶性脑膜瘤细胞(HKBMM和IOMM-Lee)、10例良性脑膜瘤、4例恶性脑膜瘤和2例孤立性纤维瘤(SFT)。
  • 类器官与亲本肿瘤具有一致的组织学特征和分子谱。
  • 公共数据库分析显示FOXM1上调与肿瘤增殖增加相关。
  • 良性脑膜瘤类器官中过表达FOXM1增加类器官增殖,恶性类器官中敲低FOXM1减少增殖。
  • thiostrepton(FOXM1抑制剂)联合放疗显著抑制恶性脑膜瘤类器官模型增殖。

临床怎么用

  • 脑膜瘤类器官模型可用于研究肿瘤生物学和筛选治疗靶点。
  • FOXM1可能作为脑膜瘤潜在治疗靶点,尤其恶性脑膜瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent comprehensive studies have revealed several molecular alterations that are frequently found in meningiomas. However, effective treatment reagents targeting specific molecular alterations have not yet been identified because of the limited number of representative research models of meningiomas. METHODS: We performed organoid cultures using meningioma cells and meningioma tumor tissues. Using immunohistochemistry and molecular analyses consisting of whole-exome sequencing, RNA-seq, and DNA methylation analyses, we compared the histological findings and molecular profiling of organoid models with those of parental tumors. Further, using these organoid models together with a public database of meningiomas, we explored molecular alterations, which are a potent treatment target for meningioma. RESULTS: We established 18 organoid models comprising of two malignant meningioma cells (HKBMM and IOMM-Lee), 10 benign meningiomas, four malignant meningiomas, and two solitary fibrous tumors (SFTs). The organoids exhibited consistent histological features and molecular profiles with those of the parental tumors. Using a public database, we identified that upregulated forkhead box M1 (FOXM1) was correlated with increased tumor proliferation. Overexpression of FOXM1 in benign meningioma organoids increased organoid proliferation; depletion of FOXM1 in malignant organoids decreased proliferation. Additionally, thiostrepton, a FOXM1 inhibitor combined with radiation therapy, significantly inhibited the proliferation of malignant meningioma organoid models. CONCLUSIONS: An organoid model for meningioma enabled us to elucidate the tumor biology of meningioma along with potent treatment targets for meningioma.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Yamazaki S, Ohka F, Hirano M, et al. Newly established patient-derived organoid model of intracranial meningioma. Neuro Oncol. 2021. PMID: 34214169. doi:10.1093/neuonc/noab155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。